HLA DR15 (DR2) Immunosuppressive Response Association in Myelodysplastic Syndrome (MDS)

TEST: 167100
Test number copied
CPT: 81377
Print Share

Synonyms

  • DR15
  • Immunosuppressive Response
  • MDS
  • Myelodysplastic Syndrome

Special Instructions

When submitting buccal swabs, please use a buccal swab kit provided by LabCorp. Please call 800-533-1037 (HLA customer service) to obtain the buccal swab kit or for assistance in selecting the proper HLA test for the patient.

Expected Turnaround Time

3 - 7 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Specimen Requirements

Specimen

Whole blood or buccal swabs

Volume

7 mL whole blood or four buccal swabs

Minimum Volume

3 mL whole blood or four buccal swabs

Container

Lavender-top (EDTA) tube or four buccal swabs in a sealed envelope (buccal swab kit). When submitting buccal swabs, please use a buccal swab kit provided by LabCorp. To obtain the buccal swab kit, please telephone 800-533-1037.

Storage Instructions

Maintain blood specimen at room temperature. Keep buccal swabs dry and at room temperature.

Causes for Rejection

Hemolysis; clotted specimen; insufficient amount of DNA on buccal swabs; yellow-top (ACD) tube

Test Details

Use

Determine the presence of DR15 antigen.

Limitations

Even with appropriate precautions, an occasional specimen may not be satisfactory for testing. In such cases, an additional specimen should be collected for testing.

This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).

Methodology

Polymerase chain reaction (PCR)/sequence-specific oligonucleotide probes (SSOP)

This is a class II antigen level test.

References

Clinical Practice Guidelines in Oncology. Version 3. Fort Washington, Pa: National Comprehensive Cancer Network (NCCN); 2006.
Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 2002 Sep 1; 100(5):1570-1574. 12176872

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
167100 HLA DR15 167101 HLA DR15 6803-1
167100 HLA DR15 167384 HLA Methodology 49549-9

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf